1.	Phase I/II Study of R-VPAM/DOX for Recurrent Sarcomas (Summary Last Modified 09/95) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: any age Sponsor: NCI Protocol IDs: CCF-IRB-1105, NCI-T94-0167D, T94-0167
2.	Phase I/II Study of R-Verapamil with EPOCH (VP-16/PRED/VCR/CTX/DOX), with Analysis of Drug Resistance Mechanisms, in Relapsed/Refractory Lymphomas and Pediatric Sarcomas and of EPOCH Alone in Previously Untreated HIV-Associated Lymphomas (Summary Last Modified 01/96) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: at least 1 year Sponsor: NCI Protocol IDs: NCI-90-C-0113E, NCI-MB-255, NCI-T90-0047N, T90-0047
3.	Phase II Study of Paclitaxel with the Multidrug Resistance Modulator Dexverapamil for Metastatic Breast Cancer (Summary Last Modified 06/95) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: TCINJ-940-1529, NCI-T94-0122O, T94-0122
4.	Phase II Study of VBL with Dexverapamil for Metastatic Renal Cell Cancer (Summary Last Modified 01/95) Phase: Phase II Type: Treatment Status: Completed Age: over 18 Sponsor: Protocol IDs: MSKCC-91120, NCI-V92-0024
5.	Phase II Pilot Study of Continuous-Infusion VIDA (VP-16/IDA/ARA-C) with or without R-Verapamil in Patients with Secondary AML or DeNovo AML in Relapse (Summary Last Modified 06/93) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-92-C-0241, NCI-MB-296, NCI-T92-0085N, T92-0085
6.	Phase I Study of TAX with R-VPAM and G-CSF in Patients with Previously Treated, Metastatic Breast Cancer (Summary Last Modified 11/94) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-92-C-0245K, NCI-MB-301, NCI-T92-0118N, T92-0118